LGT Group Foundation’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-9,262
Closed -$1.15M 262
2023
Q4
$1.15M Sell
9,262
-9,465
-51% -$967K 0.03% 199
2023
Q3
$1.77M Sell
18,727
-24,169
-56% -$2.72M 0.04% 183
2023
Q2
$5.51M Buy
42,896
+3,054
+8% +$369K 0.13% 133
2023
Q1
$4.63M Sell
39,842
-3,363
-8% -$376K 0.13% 138
2022
Q4
$4.89M Buy
43,205
+36,737
+568% +$4.03M 0.15% 125
2022
Q3
$520K Sell
6,468
-37,411
-85% -$3.17M 0.02% 215
2022
Q2
$3.27M Buy
43,879
+27,891
+174% +$2.55M 0.1% 158
2022
Q1
$2.13M Buy
15,988
+13,312
+497% +$1.46M 0.05% 188
2021
Q4
$359K Buy
+2,676
New +$385K 0.01% 237

Other funds holding DXCM

LGT Group Foundation's DXCM Position: Q1 2024 in Review

LGT Group Foundation sold out of DexCom (DXCM) in Q1 2024, closing a stake of 9,262 shares — an estimated $1.15M sold.

LGT Group Foundation first reported a position in DXCM in Q4 2021 and held it in 9 quarters. The position peaked at $5.51M in Q2 2023. 1,032 funds tracked by Wall St. Rank hold DXCM as of Q1 2024.

  • LGT Group Foundation reported no remaining DexCom position as of Q1 2024 after selling out during the quarter.
  • LGT Group Foundation sold 9,262 DexCom shares in Q1 2024, an estimated $1.15M.
  • LGT Group Foundation first reported a position in DexCom in Q4 2021 and held it in 9 quarters.
  • LGT Group Foundation's DexCom position peaked at $5.51M in Q2 2023.
  • 1,032 funds tracked by Wall St. Rank held DexCom as of Q1 2024.

Based on LGT Group Foundation's 13F filing for Q1 2024, filed 14 May 2024.